Raymond A. Farkouh, United States of America

Pfizer Inc. Health Economics and Outcomes Research

Presenter of 1 Presentation

 Conference Calendar

TWENTY YEAR IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE ON INVASIVE PNEUMOCOCCAL DISEASE SYNDROMES IN US CHILDREN LESS THAN 5 YEARS OF AGE (ID 243)

Session Name
Vaccines - Impact of Vaccine programs and Serotype Replacement
Presenter
Authors

Author Of 3 Presentations

 Conference Calendar

TWENTY YEAR IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE ON INVASIVE PNEUMOCOCCAL DISEASE SYNDROMES IN US CHILDREN LESS THAN 5 YEARS OF AGE (ID 243)

Session Name
Vaccines - Impact of Vaccine programs and Serotype Replacement
Presenter
Authors

CURRENT AND FUTURE PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPE-SPECIFIC BURDEN IN THE UNITED STATES ADULT POPULATION (ID 287)

Session Name
Population Sciences - Epidemiology, Economics, and Mathematical Modelling
Presenter
Authors

Abstract

Background

An investigational 20-valent pneumococcal conjugate vaccine (PCV20) is in development and contains the 13 serotypes in PCV13, with 7 additional serotypes 22F,33F,8,10A,11A,12F and 15B. We estimated the epidemiologic and economic burden of pneumococcal disease attributable to serotypes contained in PCV13 and PCV20 for US adults.

Methods

The burden of disease was estimated using published and unpublished data on incidence rates, serotype coverage, mortality, and costs for invasive pneumococcal disease (IPD) and pneumonia. Active Bacterial Core surveillance data from 2017 was used for IPD data. Data was extrapolated to the total US adult population, stratified by age and risk group.

Results

Results are summarized in Table. An additional 9,900 cases of IPD, 44,000 cases of inpatient pneumonia, 52,000 cases of outpatient pneumonia, and 4,300 death are estimated to be caused by the seven new serotypes in PCV20. The new serotypes account for approximately 40% of all cases, deaths, and costs. Direct costs attributed to all PCV20 serotypes are estimated at $4.2 billion.

table 1.png

Conclusions

Pneumococcal disease remains an unmet need in US adults despite increasing uptake with PCV13 and 23-valent polysaccharide vaccine. The seven new serotypes contribute substantially to the clinical and economic burden of pneumococcal disease in adults.

Hide

ESTIMATED PNEUMOCOCCAL DISEASE AND ECONOMIC BURDEN FOR CURRENT AND FUTURE VACCINE SEROTYPES IN UNITED STATES IN CHILDREN UNDER FIVE YEARS OF AGE. (ID 288)

Session Name
Population Sciences - Epidemiology, Economics, and Mathematical Modelling
Presenter
Authors

Abstract

Background

The 13-valent PCV (PCV13) has reduced vaccine preventable pneumococcal disease caused by serotypes 4,6B,9V,14,18C,19F,23F1,5,7F,3,6A,19A, with cross-protection against 6C. However, non-vaccine type burden remains in the United States (US). Higher-valent PCVs in development will contain additional serotypes 22F,33F,8,10A,11A,12F, and 15B (PCV20). We estimated the remaining clinical and economic burden attributed to current and future vaccine serotypes in US children under five.

Methods

The burden of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) was estimated by extrapolating the IPD serotype distribution from 2017 CDC Active Bacterial Core (ABC) surveillance data for PCV13 serotypes (25.0%) and PCV20 serotypes (58.1%) to current population statistics for all clinical entities. Clinical, epidemiologic, and costs data were sourced or estimated from published evidence.

Results

The estimated burden associated with PCV13 and PCV20 serotypes are in Table 1. Based on assumptions, the incremental burden is 700,000 disease cases and 69 deaths annually caused by additional serotypes contained in PCV20. This represented $445 million incremental annual direct costs in 2019 dollars.

table 1.png

Conclusions

Future PCV serotypes encompass a considerable amount of the disease burden. US infant pneumococcal disease and healthcare expenditure may be reduced if future PCVs provide comparable levels of protection as PCV13 serotypes.

Hide